Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study - Université de Bretagne Occidentale Access content directly
Journal Articles Blood Year : 2017

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Michel Tulliez
  • Function : Author
Jean-Michel Pignon
  • Function : Author
Aude Charbonnier
  • Function : Author
Hyacinthe Johnson-Ansah
  • Function : Author
Marie-Pierre Noel
  • Function : Author
François Mahon
  • Function : Author

Dates and versions

hal-02050833 , version 1 (27-02-2019)

Identifiers

Cite

Delphine Rea, Franck Nicolini, Michel Tulliez, François Guilhot, Joëlle Guilhot, et al.. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood, 2017, 129 (7), pp.846-854. ⟨10.1182/blood-2016-09-742205⟩. ⟨hal-02050833⟩
139 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More